Vertex reiterated by Merrill Lynch at neutral

Vertex Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating after accounting for the conversion of $40.5 million of 5% convertible notes due 2007 on Sept. 9. Vertex shares Tuesday were up $0.20, or 1.07%, at $18.91 on volume of 959,017 shares versus the three-month running average of 1,368,760 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.